HIGH-DOSE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CARBOPLATIN FOLLOWED BY RESCUE WITH AUTOLOGOUS BONE MARROW AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH POOR PROGNOSIS BREAST CANCER
OBJECTIVES: I. Investigate the curative potential of high-dose cyclophosphamide, etoposide,
and carboplatin followed by autologous stem cell rescue in women with breast cancer
considered incurable by conventional therapy. II. Observe the overall response rate,
survival rate, and toxicity associated with this regimen.
OUTLINE: Prior to therapy, patients undergo collection of peripheral blood stem cells (PBSC)
on another protocol; patients with marrow involvement undergo PBSC harvest only, while all
others may also undergo bone marrow harvest. All patients receive cyclophosphamide,
etoposide, and carboplatin over 4 consecutive days, followed 3 days later by PBSC or bone
marrow and granulocyte colony-stimulating factor. Patients are followed for duration of
remission and survival.
PROJECTED ACCRUAL: 100-200 patients will be entered.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Thomas R. Klumpp, MD
Fox Chase Cancer Center
United States: Federal Government
|Temple University Cancer Center||Philadelphia, Pennsylvania 19140|